Literature DB >> 23794501

Major active components in grapefruit, orange, and apple juices responsible for OATP2B1-mediated drug interactions.

Yoshiyuki Shirasaka1, Megumi Shichiri, Takanori Mori, Takeo Nakanishi, Ikumi Tamai.   

Abstract

We aimed to explore the major active components in grapefruit juice (GFJ), orange juice (OJ), and apple juice (AJ) that are responsible for OATP2B1-mediated drug interactions, by means of in vitro studies using Xenopus oocytes expressing OATP2B1 with a typical OATP2B1 substrate, estrone-3-sulfate. All three juices inhibited OATP2B1-mediated estrone-3-sulfate uptake with half-maximum inhibition (IC50 ) values of 0.222% (GFJ), 0.807% (OJ), and 2.27% (AJ). Eight major flavonoids (naringin, naringenin, hesperidin, hesperetin, phloridzin, phloretin, quercetin, and kaempferol) contained in the juices inhibited OATP2B1-mediated estrone-3-sulfate uptake with IC50 values of 4.63, 49.2, 1.92, 67.6, 23.2, 1.31, 9.47, and 21.3 μM, respectively. When the concentration-IC50 ratios ([C]/IC50 ) of these flavonoids in GFJ, OJ, and AJ were calculated, values of [C]/IC50 ≥ 100 were obtained for naringin in GFJ and hesperidin in OJ. No flavonoid in AJ showed a ratio higher than unity. However, significant inhibition of OATP2B1 was observed with a mixture of phloridzin, phloretin, hesperidin, and quercetin at the concentrations present in AJ. In conclusion, our results indicate that naringin and hesperidin are the major OATP2B1 inhibitors in GFJ and OJ, respectively, whereas a combination of multiple components appears to be responsible for OATP2B1 inhibition by AJ.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  OATP2B1; Organic anion-transporting polypeptide transporters; apple juice; flavonoid; food interactions; grapefruit juice; interaction; intestinal absorption; intestinal secretion/transport; orange juice

Mesh:

Substances:

Year:  2013        PMID: 23794501     DOI: 10.1002/jps.23653

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Prioritizing pharmacokinetic drug interaction precipitants in natural products: application to OATP inhibitors in grapefruit juice.

Authors:  Emily J Johnson; Christina S Won; Kathleen Köck; Mary F Paine
Journal:  Biopharm Drug Dispos       Date:  2017-02-14       Impact factor: 1.627

2.  Evidence of reduced oral bioavailability of paracetamol in rats following multiple ingestion of grapefruit juice.

Authors:  Nidal A Qinna; Obbei A Ismail; Tawfiq M Alhussainy; Nasir M Idkaidek; Tawfiq A Arafat
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-30       Impact factor: 2.441

3.  Interaction of soy isoflavones and their main metabolites with hOATP2B1 transporter.

Authors:  Lucie Navrátilová; Lenka Applová; Pavel Horký; Přemysl Mladěnka; Petr Pávek; František Trejtnar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-22       Impact factor: 3.000

4.  Functional identification of organic cation transporter 1 as an atenolol transporter sensitive to flavonoids.

Authors:  Yoshihisa Mimura; Tomoya Yasujima; Kinya Ohta; Katsuhisa Inoue; Hiroaki Yuasa
Journal:  Biochem Biophys Rep       Date:  2015-06-24

Review 5.  Interactions between Food and Drugs, and Nutritional Status in Renal Patients: A Narrative Review.

Authors:  Claudia D'Alessandro; Alessia Benedetti; Antonello Di Paolo; Domenico Giannese; Adamasco Cupisti
Journal:  Nutrients       Date:  2022-01-04       Impact factor: 5.717

6.  The Pharmacokinetic Exposure to Fexofenadine is Volume-Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice.

Authors:  J Luo; H Imai; T Ohyama; S Hashimoto; T Hasunuma; Y Inoue; T Kotegawa; K Ohashi; N Uemura
Journal:  Clin Transl Sci       Date:  2016-05-19       Impact factor: 4.689

7.  Does consumption of red grapefruit juice alter naringenin concentrations in milk produced by breastfeeding mothers?

Authors:  Ewa Romaszko; Urszula Marzec-Wróblewska; Anna Badura; Adam Buciński
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.